Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Penn Medicine (University of Pennsylvania)

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1361
Shown on this page
12
Current sort
Recently updated
Campus scope
Penn Medicine (University of Pennsylvania), Philadelphia, PA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Penn Medicine (University of Pennsylvania), Philadelphia, PA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 361–372 of 1,361 matching trials with a site at Penn Medicine (University of Pennsylvania), Philadelphia, PA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

NCT06402201
Status at this site: Recruiting
View directory record Official record
Conditions
Select Advanced Solid Tumors
Interventions
CDR404
Biological
Lead sponsor
CDR-Life AG
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Miami, Florida • Ann Arbor, Michigan • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:46 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Imaging Sex Differences in Smoking-Induced Pulmonary Inflammation

NCT03721822
Status at this site: Recruiting
View directory record Official record
Conditions
Smoking, Cigarette, Smoking E-cigarette, Healthy Volunteer
Interventions
[18F]NOS
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

NCT04590326
Status at this site: Recruiting
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
Interventions
REGN5668, Cemiplimab, Ubamatamab, Sarilumab, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
13
States / cities
Duarte, California • Irvine, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:46 PM EDT
Recruiting Phase 2 Interventional

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

NCT07489651
Status at this site: Recruiting
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
RE104 for Injection, Placebo
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 74 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:46 PM EDT
Active, not recruiting Not applicable Interventional Results available

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

NCT03614260
Site status not listed — check the official record
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Paradise Renal Denervation System, Renal Angiogram
Device · Procedure
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Bridgeport, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:46 PM EDT
Active, not recruiting Phase 4 Interventional

Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

NCT06712407
Site status not listed — check the official record
View directory record Official record
Conditions
IgA Nephropathy
Interventions
TARPEYO®
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
37
States / cities
Birmingham, Alabama • Glendale, Arizona • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:46 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Communication Strategies to Increase HPV Vaccinations

NCT06784960
Site status not listed — check the official record
View directory record Official record
Conditions
Papilloma Viral Infection, Vaccine Hesitancy, Communication
Interventions
HPV Message 1, HPV Message 2, HPV Message 3, Control Message, Provider Strong-Recommendation Toolkit
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
9,002 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:46 PM EDT
Recruiting Phase 3 Interventional

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

NCT07157774
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Interventions
Muvalaplin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
10,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
159
States / cities
Birmingham, Alabama • Apache Junction, Arizona • Gilbert, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:46 PM EDT
Recruiting Phase 1 Interventional

A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

NCT07148089
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
SGT-501
Drug
Lead sponsor
Solid Biosciences Inc.
Industry
Eligibility
7 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:46 PM EDT
Active, not recruiting Phase 2 Interventional

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

NCT06066957
Site status not listed — check the official record
View directory record Official record
Conditions
Cytomegalovirus Infections, Transplant-Related Disorder
Interventions
Letermovir 480 MG [Prevymis]
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:46 PM EDT
Recruiting Not applicable Interventional

THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension

NCT06559891
Status at this site: Recruiting
View directory record Official record
Conditions
Hypertension
Interventions
TIVUS™ Renal Denervation System, Sham
Device · Other
Lead sponsor
SoniVie Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
34
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:46 PM EDT
Recruiting Phase 3 Interventional

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

NCT06475989
Status at this site: Recruiting
View directory record Official record
Conditions
Refractory Differentiated Thyroid Gland Carcinoma
Interventions
Biospecimen Collection, Cabozantinib, Computed Tomography, Dabrafenib, Magnetic Resonance Imaging, Questionnaire Administration, Trametinib
Procedure · Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
307
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 222 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 25, 2026, 4:46 PM EDT

About this Penn Medicine (University of Pennsylvania) institution page

What this page lists
ClinicalTrials.gov records that list Penn Medicine (University of Pennsylvania) in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of Pennsylvania at any site, browse by condition, or browse by U.S. city.